

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104  
Estimated average burden  
hours per response: 0.5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>NEMMERS JOSEPH M</u>	2. Date of Event Requiring Statement (Month/Day/Year) 09/15/2003	3. Issuer Name and Ticker or Trading Symbol <u>ABBOTT LABORATORIES [ ABT ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> Officer (give title below) <u>Senior Vice President</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person  Form filed by More than One Reporting Person
(Last) (First) (Middle) <u>100 ABBOTT PARK ROAD</u>			
(Street) <u>ABBOTT PARK</u> IL <u>60064-6400</u>			
(City) (State) (Zip)			

## Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares without par value	39,901	D	
Common shares without par value	10,274 <sup>(1)</sup>	I	profit sharing trust
Common shares without par value	328 <sup>(2)</sup>	I	by self for son
Common shares without par value	328 <sup>(2)</sup>	I	by self for son
Common shares without par value	275 <sup>(2)</sup>	I	by self for son
Common shares without par value	269 <sup>(2)</sup>	I	by self for son

Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Option (right to buy) <sup>(3)</sup>	02/09/1999	02/08/2006	Common shares	6,358	21.85	D	
Option (right to buy) <sup>(3)</sup>	02/14/2000	02/13/2007	Common shares	3,946	29.19	D	
Option (right to buy) <sup>(3)</sup>	02/13/2000	02/12/2008	Common shares	4,070	37	D	
Option (right to buy) <sup>(3)</sup>	02/13/2001	02/12/2008	Common shares	2,930	37	D	
Option (right to buy) <sup>(3)</sup>	02/12/2001	02/11/2009	Common shares	4,885	45.22	D	
Option (right to buy) <sup>(3)</sup>	02/12/2002	02/11/2009	Common shares	2,515	45.22	D	
Option (right to buy) <sup>(3)</sup>	02/11/2003	02/10/2010	Common shares	2,881	34.7	D	
Option (right to buy) <sup>(3)</sup>	02/09/2003	02/08/2011	Common shares	10,667	48.36	D	
Option (right to buy) <sup>(3)</sup>	02/09/2004	02/08/2011	Common shares	5,333	48.36	D	
Option (right to buy) <sup>(3)</sup>	12/03/2002	12/02/2011	Common shares	3,334	55.375	D	
Option (right to buy) <sup>(3)</sup>	12/03/2003	12/02/2011	Common shares	3,333	55.375	D	
Option (right to buy) <sup>(3)</sup>	12/03/2004	12/02/2011	Common shares	3,333	55.375	D	
Option (right to buy) <sup>(3)</sup>	02/15/2003	02/14/2012	Common shares	13,334	57.06	D	
Option (right to buy) <sup>(3)</sup>	02/15/2004	02/14/2012	Common shares	13,333	57.06	D	
Option (right to buy) <sup>(3)</sup>	02/15/2005	02/14/2012	Common shares	13,333	57.06	D	
Option (right to buy) <sup>(3)</sup>	10/25/2002	04/28/2004	Common shares	719	54.58	D	
Option (right to buy) <sup>(3)</sup>	10/25/2002	04/27/2005	Common shares	1,863	54.58	D	
Option (right to buy) <sup>(3)</sup>	10/25/2002	02/08/2006	Common shares	1,476	54.58	D	

**Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Option (right to buy) <sup>(3)</sup>	10/25/2002	02/13/2007	Common shares	2,980	54.58	D	
Option (right to buy) <sup>(3)</sup>	10/25/2002	02/10/2010	Common shares	3,568	54.58	D	
Option (right to buy) <sup>(3)</sup>	06/28/2003	06/27/2012	Common shares	6,500	38.73	D	
Option (right to buy) <sup>(3)</sup>	06/28/2004	06/27/2012	Common shares	6,500	38.73	D	
Option (right to buy) <sup>(3)</sup>	06/28/2005	06/27/2012	Common shares	6,500	38.73	D	
Option (right to buy) <sup>(3)</sup>	06/03/2003	02/10/2010	Common shares	2,027	43.78	D	
Option (right to buy) <sup>(3)</sup>	02/14/2004	02/13/2013	Common shares	20,000	35.36	D	
Option (right to buy) <sup>(3)</sup>	02/14/2005	02/13/2013	Common shares	20,000	35.36	D	
Option (right to buy) <sup>(3)</sup>	02/14/2006	02/13/2013	Common shares	20,000	35.36	D	
Option (right to buy) <sup>(3)</sup>	12/01/2003	02/10/2010	Common shares	457	43.82	D	

**Explanation of Responses:**

- Balance in the Abbott Laboratories Stock Retirement Trust as of September 19, 2003
- Reporting person disclaims beneficial ownership of all securities held by his sons.
- Employee stock options granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3.

John A. Berry, Attorney-in-Fact for Joseph M. Nemmers      09/24/2003

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

**POWER OF ATTORNEY**

The undersigned constitutes and appoints JOSE M. DE LASA, BRIAN J. SMITH, and JOHN A. BERRY, and each of them individually, as the undersigned's true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, to sign any and all Securities and Exchange Commission ("SEC") statements of beneficial ownership of securities on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done under said Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC. The authorization set forth above shall continue in full force and effect until the undersigned revokes such authorization by written instructions to the attorney-in-fact.

Dated: September 23, 2003

/s/ Joseph M. Nemmers

---

**Signature of Reporting Person**

Joseph M. Nemmers

Senior Vice President

---

**Name and Title**

Abbott Laboratories  
100 Abbott Park Road  
Abbott Park, IL 60064-6400

---